RxDoctor Payments DataLook up a doctor →

Stacey Bederman, MD

Orthopaedic Surgery of the Spine · Orange, CANPI 1316190085

Payments from drug & device makers

$3,731,246in general payments, 2019–2025

Across 460 payments — averaging $8111.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spineart SA$1.8M
  • Alphatec Spine, Inc$1.7M
  • Spineart USA Inc$70K
  • Kyocera Medical Technologies, Inc.$68K
  • Globus Medical$3K
  • Novapproach Spine, LLC$2K
  • plus $7K from 35 others

What the payments were for

  • Royalty or licence$3,571,30696%
  • Consulting fees$129,1463%
  • Travel & lodging$17,2970%
  • Food & beverage$13,4980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,731,246 in reported general payments places this provider in the 95th percentile of 288 orthopaedic surgery of the spine providers in California.

See all orthopaedic surgery of the spine providers in California

Medicare billing

Part B allowed, 2024
$699,135
Medicare patients
382
Services billed
5,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide32$81,231
Gabapentin126$1,287
Naproxen43$546
Pregabalin41$462
Methylprednisolone48$330
Tramadol Hcl68$226
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$202
Amitriptyline Hcl26$175
Celecoxib20$168
Cyclobenzaprine Hcl20$150
Methocarbamol15$141
Baclofen17$122
Ibuprofen13$107
Diazepam21$20
Meloxicam16$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$611$81,23132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 288 orthopaedic surgery of the spine providers in California.

Other orthopaedic surgery of the spine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →